000838516 000__ 05674cam\a2200541Ii\4500
000838516 001__ 838516
000838516 005__ 20230306144546.0
000838516 006__ m\\\\\o\\d\\\\\\\\
000838516 007__ cr\un\nnnunnun
000838516 008__ 180411s2018\\\\sz\a\\\\o\\\\\001\0\eng\d
000838516 019__ $$a1031449016$$a1031525175$$a1031906243$$a1034551146
000838516 020__ $$a9783319751849$$q(electronic book)
000838516 020__ $$a3319751840$$q(electronic book)
000838516 020__ $$z9783319751832
000838516 020__ $$z3319751832
000838516 0247_ $$a10.1007/978-3-319-75184-9$$2doi
000838516 035__ $$aSP(OCoLC)on1030993066
000838516 035__ $$aSP(OCoLC)1030993066$$z(OCoLC)1031449016$$z(OCoLC)1031525175$$z(OCoLC)1031906243$$z(OCoLC)1034551146
000838516 040__ $$aGW5XE$$beng$$erda$$epn$$cGW5XE$$dN$T$$dYDX$$dEBLCP$$dOCLCF$$dAZU$$dCOO$$dUAB$$dOCLCQ
000838516 049__ $$aISEA
000838516 050_4 $$aRC280.L9
000838516 08204 $$a616.99/446061$$223
000838516 24500 $$aResistance of targeted therapies excluding antibodies for lymphomas /$$cAndrés J. M. Ferreri, editor.
000838516 264_1 $$aCham, Switzerland :$$bSpringer,$$c2018.
000838516 300__ $$a1 online resource (xiii, 138 pages) :$$billustrations.
000838516 336__ $$atext$$btxt$$2rdacontent
000838516 337__ $$acomputer$$bc$$2rdamedia
000838516 338__ $$aonline resource$$bcr$$2rdacarrier
000838516 347__ $$atext file$$bPDF$$2rda
000838516 4901_ $$aResistance to targeted anti-cancer therapeutics,$$x2196-5501 ;$$vvolume 17
000838516 500__ $$aIncludes index.
000838516 5050_ $$aIntro; "Resistance to Targeted Anti-Cancer Therapeutics": Aims and Scope; Series Editor Biography; Acknowledgements; Editor's Biography; Preface; Contents; BTK Inhibitors: Focus on Ibrutinib and Similar Agents; Introduction; Ibrutinib Biochemical Structure, PK, PD, Routes and Doses; Ibrutinib: Efficacy and Safety Clinical Data; Resistance to BTK Inhibitors; Clinical Studies on Resistance Mechanisms in CLL; Prognosis After Disease Progression and Transformation in CLL; Resistance Mechanisms in MCL; Clinical Trials and Resistance Mechanisms in Waldenström's Macroglobulinemia
000838516 5058_ $$aOther BTK InhibitorsConclusion; References; BCL2 Inhibitors: Insights into Resistance; Introduction; BCL2 and Cancer; BH3 Mimetics; ABT-737; Navitoclax; Venetoclax; Biochemistry; Pre-clinical Data; Administration and Pharmacokinetics; Clinical Outcomes; Clinical Effect of Resistance; Molecular Mechanisms of Resistance; Conclusion; References; Proteasome Inhibitors with a Focus on Bortezomib; Introduction; The Ubiquitin Proteasome System; Proteasome Inhibitors: Mechanism of Anti-tumor Effect; Cell Intrinsic Mechanisms of Resistance; Proteasome Subunit Mutations; Efflux Pumps; Autophagy
000838516 5058_ $$aPlasmacytic DifferentiationProteasome Subunit Expression; BCL-2; Cell Extrinsic Mechanisms of Resistance; Interleukin-6; The Hedgehog Pathway; Overcoming Bortezomib Resistance; Targeting the Immature Plasma Cell; Differentiation Induction; Synergistically Activating the Unfolded Protein Response; BCL-2 Inhibition; Conclusion; References; IMiD: Immunomodulatory Drug Lenalidomide (CC-5013; Revlimid) in the Treatment of Lymphoma: Insights into Clinical Use and Molecular Mechanisms; Introduction; Non-Hodgkin's Lymphoma; Lenalidomide for the Treatment of Lymphoma
000838516 5058_ $$aStructure and Mechanism of ActionToxicities; Other Insights from Preclinical Models; Clinical Indications and Data; Predictive Markers for Lenalidomide in Patients with Lymphoma; Molecular Mechanisms of Resistance; Future Directions; References; mTOR Inhibitors, with Special Focus on Temsirolimus and Similar Agents; Introduction: Rapamycin and Rapalogs History; The mTOR Pathway and mTOR Inhibitors; Pharmacokinetics of Rapalogs; Toxicity; Pneumonitis; Metabolic Adverse Events; Hematological Toxicities; mTOR Inhibitors Associated Stomatitis (mIAS); Mechanisms of Resistance; Mutations of mTOR
000838516 5058_ $$aGenetic and Functional HeterogeneityAlternative Proliferation Pathways; Molecular Mechanisms of mTOR Activation in Lymphomas; Summary of Clinical Trials; Temsirolimus; Everolimus; Ridaforolimus; Second Generation mTOR Inhibitors; Summary; References; Inhibitors of the JAK/STAT Pathway, with a Focus on Ruxolitinib and Similar Agents; The JAK/STAT Intracellular Signaling Pathway; Deregulated JAK/STAT Signaling in Lymphomagenesis; Mutations that Alter JAK2 Copy Number but Not Its Coding Sequence; Mutations that Directly Alter the JAK Family Members; Mutations that Target the STAT Family Members
000838516 506__ $$aAccess limited to authorized users.
000838516 520__ $$aIn the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance. .
000838516 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed April 11, 2018).
000838516 650_0 $$aLymphomas$$xChemotherapy.
000838516 650_0 $$aDrug targeting.
000838516 7001_ $$aFerreri, Andrés J. M.$$eeditor.
000838516 77608 $$iPrint version: $$z3319751832$$z9783319751832$$w(OCoLC)1019591912
000838516 830_0 $$aResistance to targeted anti-cancer therapeutics ;$$vv. 17.
000838516 852__ $$bebk
000838516 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-75184-9$$zOnline Access$$91397441.1
000838516 909CO $$ooai:library.usi.edu:838516$$pGLOBAL_SET
000838516 980__ $$aEBOOK
000838516 980__ $$aBIB
000838516 982__ $$aEbook
000838516 983__ $$aOnline
000838516 994__ $$a92$$bISE